Pharmacogenomic biomarkers in coronary artery disease: a narrative review.
Pamila DuaSandeep SethBhavana PrasherMitali MukerjiSubir Kumar MaulikK H ReetaPublished in: Biomarkers in medicine (2024)
Coronary artery disease (CAD) has a high mortality rate. Despite various therapeutic targets, non-responsiveness to drugs remains a prevalent issue. Pharmacogenomics assesses the way an individual's genetic attributes affect their likely response to drug therapy. Single-nucleotide polymorphisms play a crucial role in determining these outcomes. This review offers an overview of single-nucleotide polymorphisms investigated in clinical studies and their associations with drug response/nonresponse in the treatment of CAD. A total of 104 studies of whole sets of chromosomes and several genes were explored. A total of 161 polymorphisms exhibited associations with drug response/nonresponse in CAD across diverse ethnic populations. This pool can serve as a pharmacogenomic biomarker for predicting response to drug therapy in patients with CAD.
Keyphrases
- coronary artery disease
- cardiovascular events
- percutaneous coronary intervention
- coronary artery bypass grafting
- adverse drug
- genome wide
- drug induced
- clinical decision support
- heart failure
- aortic stenosis
- cardiovascular disease
- type diabetes
- acute coronary syndrome
- dna methylation
- adipose tissue
- replacement therapy
- mass spectrometry
- aortic valve
- transcription factor
- high resolution
- cell therapy
- glycemic control
- atomic force microscopy
- bioinformatics analysis